keyword
MENU ▼
Read by QxMD icon Read
search

Chemotherapy-induced thrombocytopenia

keyword
https://www.readbyqxmd.com/read/28160575/safety-and-efficacy-of-bleomycin-pingyangmycin-containing-chemotherapy-regimens-for-malignant-germ-cell-tumor-patients-in-the-female-genital-system
#1
Qianying Zhao, Dongyan Cao, Mei Yu, Jiaxin Yang, Yongjian Liu, Yang Xiang, Ming Wu, Lingya Pan, Jinghe Lang, Kaifeng Xu, Jiangna Han, Keng Shen
OBJECTIVES: To comprehensively evaluate the safety and effectiveness of bleomycin/pingyangmycin-containing chemotherapy for female patients with malignant germ cell tumors in their genital system; to assess the diagnostic value of pulmonary function tests for bleomycin-induced pulmonary toxicity. METHODS: Data from a cohort of 120 patients, collected across 25 years, was reviewed. Chemotherapy-related adverse events were routinely monitored. Pulmonary toxicity was diagnosed and graded according to serial pulmonary function testing results, and potential impact factors were explored...
February 2, 2017: Oncotarget
https://www.readbyqxmd.com/read/28152765/evaluation-of-relative-thrombocytopenia-identification-of-neuropathy-and-bleeding-risk-secondary-to-utilization-of-neuromodulating-agents-in-multiple-myeloma-patients-receiving-autologous-stem-cell-transplant-treated-with-melphalan-bortezomib-and-lenalidomide
#2
Joel Marcus, Robyn Jackson, Marco A Ruiz, Ryan Patrick Griffin, Rubina Hafeez Khan
212 Background: Chemotherapy-induced polyneuropathy (CIPN) is a crippling manifestation in multiple myeloma (MM) patients that requires attentiveness to safety and quality of life.(2) Bortezomib, lenalidomide, and melphalan are commonly utilized chemotherapy agents that can cause both CIPN(3,4) and significant myelosuppression. Within this subset of patients we wish to insure efficacy and minimization of neuropathic pain while being mindful of bleeding risks. METHODS: IRB approval was obtained for a retrospective study of patients with MM who received a bone marrow transplant (BMT)...
March 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28047407/su-f-t-110-lkb-modeling-of-acute-hematologic-toxicity-in-rectal-cancer
#3
H Deng, K Cheng, X Wan
PURPOSE: To investigate dosimetric parameters correlated with acute hematologic toxicity (HT) in patients with rectal cancer treated with IMRT and concurrent chemotherapy. METHODS: We analyzed 127 rectal cancer patients receiving IMRT and concurrent chemotherapy. Whole pelvic bone marrow (PBM) was contoured for each patient including lumbosacral spine (LSSP), ilium and lower pelvic (LP). The equivalent uniform dose (EUD) of each region and the PBM were calculated...
June 2016: Medical Physics
https://www.readbyqxmd.com/read/28001189/acute-myeloid-leukemia-after-kidney-transplantation-a-case-report-and-literature-review
#4
Francesca Cardarelli, Vanesa Bijol, Anil Chandraker, Cindy Varga, Leonardo V Riella
The incidence of malignancy is greater in kidney transplant recipients compared to the general population, though the higher risk is not equally distributed to all types of cancers. In face of the increased longevity of renal transplant recipients, certain cancers, such as acute leukemias, are becoming more prevalent. Acute myeloid leukemia (AML) typically presents with cytopenias and infections, both common findings after kidney transplantation. Therefore, the diagnosis of AML may be initially overlooked in these patients...
December 2016: Jornal Brasileiro de Nefrologia: ʹorgão Oficial de Sociedades Brasileira e Latino-Americana de Nefrologia
https://www.readbyqxmd.com/read/27986986/a-pharmacokinetic-study-of-lipegfilgrastim-in-children-with-ewing-family-of-tumors-or-rhabdomyosarcoma
#5
Margarita B Belogurova, Zoryana P Kizyma, Miklós Garami, Mónika Csóka, Michael J Lamson, Anton Buchner, Peter Bias, Andreas Lammerich
PURPOSE: Neutropenia is a common complication from chemotherapy, limiting optimal dosing and treatment. Lipegfilgrastim is a long-acting granulocyte colony-stimulating factor developed for the management of chemotherapy-induced neutropenia. The objectives of this phase 1, multinational, open-label, single-arm study were to characterize the pharmacokinetics (PK) and pharmacodynamics (PD) of a single body weight-adjusted dose of lipegfilgrastim and to evaluate the efficacy, safety, and tolerability of the drug in children with Ewing family of tumors or rhabdomyosarcoma treated with myelosuppressive chemotherapy...
January 2017: Cancer Chemotherapy and Pharmacology
https://www.readbyqxmd.com/read/27956157/ibrutinib-for-patients-with-rituximab-refractory-waldenstr%C3%A3-m-s-macroglobulinaemia-innovate-an-open-label-substudy-of-an-international-multicentre-phase-3-trial
#6
Meletios A Dimopoulos, Judith Trotman, Alessandra Tedeschi, Jeffrey V Matous, David Macdonald, Constantine Tam, Olivier Tournilhac, Shuo Ma, Albert Oriol, Leonard T Heffner, Chaim Shustik, Ramón García-Sanz, Robert F Cornell, Carlos Fernández de Larrea, Jorge J Castillo, Miquel Granell, Marie-Christine Kyrtsonis, Veronique Leblond, Argiris Symeonidis, Efstathios Kastritis, Priyanka Singh, Jianling Li, Thorsten Graef, Elizabeth Bilotti, Steven Treon, Christian Buske
BACKGROUND: In the era of widespread rituximab use for Waldenström's macroglobulinaemia, new treatment options for patients with rituximab-refractory disease are an important clinical need. Ibrutinib has induced durable responses in previously treated patients with Waldenström's macroglobulinaemia. We assessed the efficacy and safety of ibrutinib in a population with rituximab-refractory disease. METHODS: This multicentre, open-label substudy was done at 19 sites in seven countries in adults aged 18 years and older with confirmed Waldenström's macroglobulinaemia, refractory to rituximab and requiring treatment...
February 2017: Lancet Oncology
https://www.readbyqxmd.com/read/27668103/immune-thrombocytopenia-in-a-child-with-t-cell-lymphoblastic-lymphoma
#7
Kayo Tokeji, Sachi Sakaguchi, Tomoko Kurimoto, Junya Fujimura, Toshiaki Shimizu
We describe the case of a 13-year-old boy who presented with persistent thrombocytopenia during maintenance chemotherapy with mercaptopurine and methotrexate for T cell lymphoblastic lymphoma. He was diagnosed with immune thrombocytopenia (ITP) after thorough investigations for the relapse of lymphoma and was successfully treated with immunoglobulin and steroids. ITP is known to be associated with chronic lymphocytic leukemia, Hodgkin lymphoma, and various types of non-Hodgkin lymphoma but rarely with T cell non-Hodgkin lymphoma or in children...
2016: Case Reports in Hematology
https://www.readbyqxmd.com/read/27639907/-rituximab-induced-acute-thrombocytopenia-in-a-patient-with-chronic-lymphocytic-leukemia
#8
M Bobot, M Benzaquen, F Rouby, D Lebowitz, J Serratrice, J-M Durand
INTRODUCTION: Rituximab is a chimeric anti-CD20 monoclonal antibody generally well tolerated. However, a severe but rare rituximab-related immune-toxic syndrome, associating fever, chills and thrombocytopenia can occur shortly after the infusion. CASE REPORT: We report a case of severe acute rituximab-induced thrombocytopenia with favorable outcome in a patient with chronic lymphocytic leukemia and discuss the possible underlying mechanisms. CONCLUSION: Despite the potential initial severity of rituximab-induced thrombocytopenia in CLL, chemotherapy should not be discontinued; tolerance might increase as the hematologic disorder is controlled...
September 14, 2016: La Revue de Médecine Interne
https://www.readbyqxmd.com/read/27456925/factors-influencing-the-efficacy-of-platelet-transfusions-in-acute-leukemia
#9
A Wahlin, L Eliasson, H Jonsson
The efficacy of platelet transfusions was evaluated in a prospective study of 37 patients with acute leukemia. The patients received 495 platelet transfusions for chemotherapy-induced thrombocytopenia. Life table analysis was found to be useful for prediction of the platelet level after transfusion. Efficacy was positively correlated with platelet content in the concentrate, and inversely correlated with bleeding. Fever, contamination of the: concentrate by leukocytes, or previous platelet transfusions were not found to have any significant influence on the efficacy, as analyzed by multiple regression...
1990: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/27425556/gradual-thrombocytopenia-induced-by-long-term-trastuzumab-exposure
#10
M Miarons, M Velasco, L Campins, S Fernández, T Gurrera, L Lopez-Viaplana
WHAT IS KNOWN AND OBJECTIVE: Unexplained thrombocytopenia is a common clinical problem, and the possibility of drug-induced thrombocytopenia must be considered. Moreover, chemotherapy agents are known to typically cause thrombocytopenia by suppressing haematopoiesis, but they can also cause immune thrombocytopenia in which the mechanism involves antibody-mediated platelet destruction. CASE DESCRIPTION: We report a case of severe thrombocytopenia related to trastuzumab administration in which the patient exhibits a slow drift downward in platelet counts with repeated cycles of trastuzumab...
October 2016: Journal of Clinical Pharmacy and Therapeutics
https://www.readbyqxmd.com/read/27316438/a-phase-1-dose-finding-and-pharmacokinetic-study-of-gemcitabine-with-nab-paclitaxel-in-patients-with-metastatic-breast-cancer
#11
Seiji Yoshitomi, Naruto Taira, Hiroyoshi Doihara, Taeko Mizoo, Tomohiro Nogami, Takayuki Iwamoto, Takayuki Motoki, Tadahiko Shien, Yutaka Ogasawara, Junji Matsuoka, Hisashi Tsuji, Toshiharu Mitsuhashi
PURPOSE: Gemcitabine (Gem) with paclitaxel (Pac) is used for patients with metastatic breast cancer who require cytoreduction with manageable toxicities. Nanoparticle albumin-bound (nab)-Pac exhibits better efficacy and reduces the risk of hypersensitivity reactions associated with solvent-based Pac. Therefore, Gem plus nab-Pac (GA) therapy may be effective for metastatic breast cancer. The purpose of this study was to determine the maximum tolerated dose for GA therapy. METHODS: The subjects were patients with metastatic breast cancer with performance status 0 or 1 and normal hepatic, renal and marrow function...
August 2016: Cancer Chemotherapy and Pharmacology
https://www.readbyqxmd.com/read/27228575/the-effect-of-amifostine-on-differentiation-of-the-human-megakaryoblastic-dami-cell-line
#12
Hai-Tao Wang, Bo Yang, Bo Hu, Xiao-Hua Chi, Long-Long Luo, Hong-Qi Yang, Xiao-Ling Lang, Jing Geng, Chun-Xia Qiao, Yan Li, Xiao-Xiong Wu, Hong-Li Zhu, Ming Lv, Xue-Chun Lu
Amifostine is a cytoprotective drug that was initially used to control and treat nuclear radiation injury and is currently used to provide organ protection in cancer patients receiving chemotherapy. Clinical studies have also found that amifostine has some efficacy in the treatment of cytopenia caused by conditions such as myelodysplastic syndrome and immune thrombocytopenia, both of which involve megakaryocyte maturation defects. We hypothesized that amifostine induced the differentiation of megakaryocytes and investigated this by exposing the human Dami megakaryocyte leukemia cell line to amifostine (1 mmol/L)...
August 2016: Cancer Medicine
https://www.readbyqxmd.com/read/27191003/in-vivo-chemoprotective-activity-of-bovine-dialyzable-leukocyte-extract-in-mouse-bone-marrow-cells-against-damage-induced-by-5-fluorouracil
#13
Erika Evangelina Coronado-Cerda, Moisés Armides Franco-Molina, Edgar Mendoza-Gamboa, Heriberto Prado-García, Lydia Guadalupe Rivera-Morales, Pablo Zapata-Benavides, María Del Carmen Rodríguez-Salazar, Diana Caballero-Hernandez, Reyes Silvestre Tamez-Guerra, Cristina Rodríguez-Padilla
Chemotherapy treatments induce a number of side effects, such as leukopenia neutropenia, peripheral erythropenia, and thrombocytopenia, affecting the quality of life for cancer patients. 5-Fluorouracil (5-FU) is wieldy used as myeloablative model in mice. The bovine dialyzable leukocyte extract (bDLE) or IMMUNEPOTENT CRP® (ICRP) is an immunomodulatory compound that has antioxidants and anti-inflammatory effects. In order to investigate the chemoprotection effect of ICRP on bone marrow cells in 5-FU treated mice, total bone marrow (BM) cell count, bone marrow colony forming units-granulocyte/macrophage (CFU-GM), cell cycle, immunophenotypification, ROS/superoxide and Nrf2 by flow cytometry, and histological and hematological analyses were performed...
2016: Journal of Immunology Research
https://www.readbyqxmd.com/read/27167627/the-effect-of-chemotherapy-induced-anemia-on-dose-reduction-and-dose-delay
#14
Leila Family, Lanfang Xu, Hairong Xu, Kimberly Cannavale, Olivia Sattayapiwat, John H Page, Chet Bohac, Chun Chao
PURPOSE: To evaluate moderate (grade 2, hemoglobin <10 g/dl) and severe (grade 3+, hemoglobin <8 g/dl) anemia as potential risk factors for DDR in the first line course of chemotherapy. While chemotherapy-induced neutropenia has been shown to be associated with dose delay/reduction (DDR) in several studies, the effect of anemia is less well studied. METHODS: We identified 3955 Kaiser Permanente patients diagnosed with incident non-Hodgkin's lymphoma (n = 574), breast (n = 2043), lung (n = 463), gastric (n = 113), ovarian (n = 204), or colorectal cancers (n = 558) between 2010 and 2012...
October 2016: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
https://www.readbyqxmd.com/read/27161680/oc-08-multiple-functional-defects-in-platelets-from-thrombocytopenic-cancer-patients-undergoing-chemotherapy
#15
C C F M J Baaten, F C J I Moenen, Y M C Henskens, F Swieringa, R Wetzels, R van Oerle, H Ten Cate, E A M Beckers, J W M Heemskerk, P E J van der Meijden
INTRODUCTION: Severe thrombocytopenia (≤50×10(9) platelets/L) is often the consequence of hematological malignancies and intensive chemotherapy. The risk of clinically significant bleeding is increased in these patients, despite the use of prophylactic platelet transfusions. The fact that there is no clear correlation between the platelet count and the risk of hemorrhage, suggests that there are other contributing factors. The contribution of impairments in platelet and coagulant function remains poorly understood...
April 2016: Thrombosis Research
https://www.readbyqxmd.com/read/27101362/a-critical-balance-managing-coagulation-in-patients-with-glioma
#16
Erin R Morgan, Warren P Mason, Catherine Maurice
Cancer-associated thrombosis, including both arterial and venous thromboembolism (VTE), is a significant source of morbidity and mortality in patients with glioma. This risk is highest in the immediate postoperative period and is increased by chemotherapy, radiation, and corticosteroids. Systemic anticoagulation with low molecular weight heparin is the treatment of choice in both the therapeutic and prophylactic settings. However, these patients are also at risk of intracranial hemorrhage, a potentially catastrophic complication of anticoagulation, and this risk must be carefully balanced against the risk of VTE...
July 2016: Expert Review of Neurotherapeutics
https://www.readbyqxmd.com/read/27100842/regulation-of-platelet-lifespan-by-apoptosis
#17
REVIEW
Marion Lebois, Emma C Josefsson
The lifespan of platelets in circulation is brief, close to 10 days in humans and 5 days in mice. Bone marrow residing megakaryocytes produce around 100 billion platelets per day. In a healthy individual, the majority of platelets are not consumed by hemostatic processes, but rather their lifespan is controlled by programmed cell death, a canonical intrinsic apoptosis program. In the last decade, insights from genetically manipulated mouse models and pharmacological developments have helped to define the components of the intrinsic, or mitochondrial, apoptosis pathway that controls platelet lifespan...
September 2016: Platelets
https://www.readbyqxmd.com/read/27073478/effects-of-decitabine-on-megakaryocyte-maturation-in-patients-with-myelodysplastic-syndromes
#18
Kai Ding, Rong Fu, Hui Liu, Deepak Anil Nachnani, Zong-Hong Shao
Thrombocytopenia is a common, often fatal complication experienced by patients with myelodysplastic syndromes (MDS). 5-aza-2'-deoxycytidine (decitabine) has been used to treat MDS patients with thrombocytopenia with a response rate of 45-50%. However, the mechanism of its effects on megakaryocytes remains unclear. In the present study, the effect of decitabine on megakaryocyte maturation was investigated. A total of 20 MDS patients diagnosed with thrombocytopenia were enrolled, including 16 refractory anemia with excess blasts (RAEB)-1 patients and 4 RAEB-2 patients], in addition to 20 leukemia patients that had achieved complete remission and 20 healthy donors...
April 2016: Oncology Letters
https://www.readbyqxmd.com/read/27064021/minimally-myelosuppressive-asparaginase-containing-induction-regimen-for-treatment-of-a-jehovah-s-witness-with-mutant-idh1-npm1-nras-acute-myeloid-leukemia
#19
Ashkan Emadi, Najeebah A Bade, Brandi Stevenson, Zeba Singh
Treatment of patients with acute myeloid leukemia (AML) who do not wish to accept blood product transfusion, including Jehovah's Witnesses, is extremely challenging. The use of conventional chemotherapy for induction of complete remission (CR) results in profound anemia and thrombocytopenia requiring frequent transfusions of blood products, without which such treatment will be life-threatening. Finding a well tolerable, minimally myelosuppressive induction regimen for such patients with AML is a clear example of area of unmet medical need...
March 10, 2016: Pharmaceuticals
https://www.readbyqxmd.com/read/27057370/paclitaxel-induced-mds-and-aml-a-case-report-and-literature-review
#20
Udit Bhaskar Bhatnagar, Daulath Singh, Alexy Glazyrin, Jill Moormeier
Therapy related acute myelogenous leukemia (AML) and myelodysplastic syndromes (MDS) have been classically linked to alkylating agents and topoisomerase inhibitors. They constitute about 1% of all AMLs. There is less evidence on association of taxanes (paclitaxel and docetaxel) with these myeloid neoplasms. We present a case of paclitaxel therapy related acute myelogenous leukemia after treatment of endometrial cancer with a regimen containing paclitaxel and carboplatin. A 63-year-old female underwent surgery followed by a total of 6 cycles of chemotherapy with carboplatin and paclitaxel...
2016: Case Reports in Oncological Medicine
keyword
keyword
115055
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"